KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Shares Outstanding (2016 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Shares Outstanding for 13 consecutive years, with $48.0 million as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Shares Outstanding fell 89.04% year-over-year to $48.0 million, compared with a TTM value of $48.0 million through Jul 2022, down 89.04%, and an annual FY2021 reading of $45.0 million, up 12.5% over the prior year.
  • Shares Outstanding was $440.0 million for Q3 2022 at Thermo Fisher Scientific, roughly flat from $440.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $440.0 million in Q2 2022 and bottomed at $27.0 million in Q2 2018.
  • Average Shares Outstanding over 5 years is $258.2 million, with a median of $430.5 million recorded in 2018.
  • Peak annual rise in Shares Outstanding hit 1492.59% in 2018, while the deepest fall reached 93.46% in 2018.
  • Year by year, Shares Outstanding stood at $432.0 million in 2018, then rose by 0.46% to $434.0 million in 2019, then increased by 0.69% to $437.0 million in 2020, then tumbled by 89.7% to $45.0 million in 2021, then grew by 6.67% to $48.0 million in 2022.
  • Business Quant data shows Shares Outstanding for TMO at $48.0 million in Q3 2022, $440.0 million in Q2 2022, and $45.0 million in Q4 2021.